tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000014272 /10-K filed Feb 11, 2026, compared with Feb 12, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
AMGNMDTBMYPFEABTTMO
NYSE Health care · Pharmaceuticals

Bristol Myers Squibb BMY

BMY quote by TradingView

Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. 10-K, Item 1

Employees
32,500
Headquarters
Princeton, NJ
CEO
Christopher S. Boerner
Next results
around Feb 4, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $48.2B through the costs to a net profit of $7.1B · income statement of the 10-K

15% net margin
Revenue to Gross profit: $34.3BRevenue to Cost of revenue: $13.9BGross profit to Net profit: $7.1BGross profit to Costs, tax, other: $27.2B Revenue: $48.2B REVENUE $48.2B +0% Y/Y Gross profit: $34.3B · 71% margin GROSS PROFIT $34.3B 71% margin Cost of revenue: $13.9B · 29% of revenue COST OF REVENUE $13.9B 29% of revenue Net profit: $7.1B · 15% margin NET PROFIT $7.1B 15% margin Costs, tax, other: $27.2B · 56% of revenue COSTS, TAX, OTHER $27.2B 56% of revenue
Gross profit $34.3B 71% margin
Net profit $7.1B 15% margin
The full income statement, year by year

BMY among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: -0.2%, above 10% of 59 peers (their median 7.2%) REVENUE GROWTH -0.2% · above 10% Gross margin: 69.2%, above 68% of 50 peers (their median 64.2%) GROSS MARGIN 69.2% · above 68% Net margin: 18.5%, above 76% of 59 peers (their median 9.5%) NET MARGIN 18.5% · above 76% FCF margin: 18.6%, above 64% of 55 peers (their median 15.2%) FCF MARGIN 18.6% · above 64%
BMY Peer median Below the median

What changed

7 new risk paragraphs. 10-K filed Feb 11, 2026 against Feb 12, 2025.

Risk factors
7 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Accounting checks
10 other checks clear
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
3 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

10 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 10 checks found nothing to note

  • Receivables +6.4% vs revenue -0.2% (+6.7 pts)
  • Cash from operations $14.2B vs net income $7.1B (FY ending Dec 31, 2025)
  • Inventory +5.2% vs revenue -0.2% (+5.4 pts)
7 more checks with nothing to note
  • Same auditor in both 10-Ks: DELOITTE & TOUCHE LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

7 paragraphs in Risk Factors that were not in the 10-K filed Feb 12, 2025. Quoted as filed.

All 7 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 12, 2025 10-K, ITEM 1A
    The U.S. and other countries have recently imposed, and may continue to impose, new tariffs. While pharmaceuticals are largely exempt from the tariffs imposed in 2025, such exemptions may be terminated or may not apply to any future tariffs. In accordance with the U.S. Government Agreement, BMS will receive certain U.S. tariff relief…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$46.2B$45.0B$48.3B$48.2B
Net income$6.3B$8.0B−$8.9B$7.1B
Operating cash flow$13.1B$13.9B$15.2B$14.2B
Free cash flow$11.9B$12.7B$13.9B$12.8B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$48.2B ▼ 0.2% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

Bristol Myers Squibb, Princeton, NJ · from the 10-K filed Feb 11, 2026

Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases.

Headquarters
Princeton, NJ
Country
United States
Listed on
NYSE
Fiscal year ends
December 31
Last results
Oct 29, 2026
Incorporated in
DE

Employees, at the top of the page: "Demographics: As of December 31, 2025, we had approximately 32,500 employees in 43 countries" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 11, 2026 (open at SEC), compared with the 10-K filed Feb 12, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BMY/export.csv") into a cell.